Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Top Cited Papers
- 17 February 2015
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 112 (9), E966-E972
- https://doi.org/10.1073/pnas.1500712112
Abstract
Monoclonal antibodies can block cellular interactions that negatively regulate T-cell immune responses, such as CD80/CTLA-4 and PD-1/PD1-L, amplifying preexisting immunity and thereby evoking antitumor immune responses. Ibrutinib, an approved therapy for B-cell malignancies, is a covalent inhibitor of BTK, a member of the B-cell receptor (BCR) signaling pathway, which is critical to the survival of malignant B cells. Interestingly this drug also inhibits ITK, an essential enzyme in Th2 T cells and by doing so it can shift the balance between Th1 and Th2 T cells and potentially enhance antitumor immune responses. Here we report that the combination of anti–PD-L1 antibody and ibrutinib suppresses tumor growth in mouse models of lymphoma that are intrinsically insensitive to ibrutinib. The combined effect of these two agents was also documented for models of solid tumors, such as triple negative breast cancer and colon cancer. The enhanced therapeutic activity of PD-L1 blockade by ibrutinib was accompanied by enhanced antitumor T-cell immune responses. These preclinical results suggest that the combination of PD1/PD1-L blockade and ibrutinib should be tested in the clinic for the therapy not only of lymphoma but also in other hematologic malignancies and solid tumors that do not even express BTK.Keywords
Funding Information
- HHS | National Institutes of Health (P01 CA034233)
This publication has 28 references indexed in Scilit:
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor ItselfThe Journal of Immunology, 2007
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-upCancer Research, 2006
- Building of the Tetraspanin Web: Distinct Structural Domains of CD81 Function in Different Cellular CompartmentsMolecular and Cellular Biology, 2006
- Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal CancerClinical Cancer Research, 2005
- Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetProceedings of the National Academy of Sciences of the United States of America, 2004
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004
- A novel orthotopic model of breast cancer metastasis to boneClinical & Experimental Metastasis, 1999